-
Long-term Risankizumab Treatment Outperforms Placebo in PsA
24 Apr 2024 00:55 GMT
… 47;National Psoriasis Foundation) endorse a specialized treatment approach for … to the development of a number of treatments for … synthetic disease-modifying antirheumatic drugs (csDMARDs).
In both … controlled trials. J Dermatolog Treat. 2024;35(1):2342383 …
-
Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis
23 Apr 2024 20:30 GMT
… and Teva Pharmaceuticals) has been approved by the FDA as a … the treatment of immune-mediated diseases such as psoriasis and …
The AVT04-GL-301 trial sought to demonstrate equivalent … reference product, facilitated the development program’s success,” added …
-
Recommendations for Effective Medication for Itchy Skin at the Pharmacy
23 Apr 2024 19:17 GMT
… recommendations for itching medication in pharmacies that can treat various causes … a drug for treating skin diseases, such as inflammatory psoriasis and … is repeated and requires treatment. If you suffer from … 47; the class of hard drugs. You should only get …
-
Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales
23 Apr 2024 17:15 GMT
Pictured: Novartis headquarters in Basel, Switzerland/iStock, Kannan D
Swiss drugmaker Novartis reported first-quarter 2024 financial results Tuesday beating consensus expectations in profit and sales driven by strong demand for blockbuster heart …
-
Novartis raises forecasts as top drug sales beat Wall Street estimates
23 Apr 2024 17:23 GMT
… of Novartis drugs for heart failure, psoriasis and multiple sclerosis … , helping the Swiss pharmaceutical company report first quarter … has grown following new treatment guidelines for heart failure … use treating metastatic prostate cancer ahead of drugs known …
-
CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment
23 Apr 2024 15:30 GMT
… the US Food and Drug Administration (FDA) issued a complete response … therapy is under development for the treatment of recessive dystrophic … VYJUVEK) was recently approved to treat DEB; Amy Paller, MD … Stanford Bullous Disease and Psoriasis Clinics.5
“You want …
-
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr.…
23 Apr 2024 12:00 GMT
… GLOBE NEWSWIRE) -- Recludix Pharma, a leader in … erythematosus, multiple sclerosis, psoriasis, and vasculitis. Earlier … small molecule drug discovery, nonclinical development and translation … including those supporting successful drugs Harvoni and Veklury. …
-
Deciphering p19 Targeting by Anti-IL-23 Biologics: Insights into Psoriasis Treatment Efficacy
22 Apr 2024 18:53 GMT
The following is a summary of “Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis,” published in the March 2024 issue of Dermatology by Daniele, et al.
IL-23 plays a central role in the …
-
UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults
23 Apr 2024 11:28 GMT
… European Commission (EC) to treat active moderate-to-severe … in the EU to treat plaque psoriasis, psoriatic arthritis and … maintained to week 48.
Treatment with Bimzelx also resulted … severe plaque psoriasis.
Pooled data for the drug from treatment initiation …
-
Expanded use of Cosentyx drug sees Novartis raise expectations
23 Apr 2024 10:47 GMT
… increased use of its psoriasis and arthritis drug Cosentyx.
Novartis said it … use of Cosentyx, particularly for treating hidradenitis suppurativa, along with the … ’s heart failure drug Entresto, and multiple sclerosis drug Kesimpta.
Despite Entresto …